NCT06799234View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Rift Valley Fever
Interventions
BIOLOGICAL

ChAdOx1 RVF

One 0.36mL dose contains 5x10\^10vp ChAdOx1 RVF.

BIOLOGICAL

Rabies Vaccine

1mL per dose

Trial Locations (1)

254

RECRUITING

KEMRI-Wellcome Trust Research Programme, Kilifi

All Listed Sponsors
lead

University of Oxford

OTHER

NCT06799234 - Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) | Biotech Hunter | Biotech Hunter